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An altered oral microbiota has been linked with the development of several oral diseases,
such as dental caries, periodontal disease, and oral stomatitis. Moreover, poor oral
health has been linked to head and neck cancer, particularly oral cancer. In recent
years a growing number of studies indicate that oral microbiota could be involved in
the development of primary tumours outside of head and neck region. The aim of this
article is to review the recent studies based on high-throughput technology to present
evidences of a relationship between oral microbiota and “non-head and neck tumours.”
Oral dysbiosis seem to be more pronounced in patients with tumours of gastrointestinal
tract, in particular oesophageal, gastric, pancreatic, and colorectal cancers, paving the
way for developing specific oral microbiota test to allow early cancer detection. Regarding
other tumour types, the results are promising but highly preliminary and still debated.
Currently, there are several factors that limit the generalization of the results, such as the
small sample size, the lack of adequate clinical information about patients, the different
sequencing techniques used, and biological sample heterogeneity. Although only at the
beginning, the analysis of oral microbiota could be the next step in the evolution of cancer
therapy and will help clinicians to develop individualised approaches to cancer prevention
and treatment.
Keywords: oral microbiota, oral microbiome, pancreatic cancer, gastrointestinal tract cancer, high-throughput
sequencing
INTRODUCTION
The term “oral microbiota” refers to the heterogeneous group of microbial species colonizing all
the oral cavity surfaces (Le Bars et al., 2017). In particular, about 700 bacterial species have been
identified in oral cavity and, more importantly, 35% of them have not been cultured (Farrell et al.,
2012). Indeed, themain limitation of microbial culture is the inability to identify the actual diversity
of oral microbiota. To determine bacterial ecosystem as a whole, high-throughput sequencing
methods have been developed, representing a leap toward characterization of oral microbial
community (Benn et al., 2018). Currently, the most common approach to analyse oral microbiota
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is genome sequencing, through the analysis of 16S rDNA gene
sequences. Indeed, the identification of this conserved DNA
sequence has provided a universal system for the identification
of bacteria. Recently, results from studies based on genome
sequencing have started shedding light on the existence of
site-specific microbial patterns that might be considered as
“healthy/normal oral microbiota” (García-Castillo et al., 2016).
The main obstacle to this definition is the highly variable
composition of microbial community due to multiple factors,
such as diet, age, and site (Arweiler and Netuschil, 2016).
Nevertheless, ecological imbalance of microbial community,
called dysbiosis, has been extensively studied both in human
and animal models. It is characterised by: loss of beneficial
microbes, expansion of pathogenic microbes, and general loss
of microbial diversity (Meurman and Uittamo, 2008; Petersen
and Round, 2014). It is becoming evident that the dysbiosis can
lead to cancer development (Schwabe and Jobin, 2013). Three
paradigms were proposed to describe the pathogenetic processes
involving the microbiota in cancer development: trigger of
chronic inflammation and immune responses that promote
tumorigenesis and tumour growth; altered metabolic activity
leading to increased production of toxic metabolites; abrogation
of virus latency leading tomalignancies (Plottel and Blaser, 2011).
An increasing number of studies have shown that oral
microbiota plays a role in the development of oral diseases,
such as dental caries, periodontal disease, and oral stomatitis
(Santarelli et al., 2015; Zhang et al., 2018). Poor oral hygiene
and periodontal disease have been linked to oral cancer, and
increasing evidences suggest that oral microbiota have a role
in oral cancer development (García-Castillo et al., 2016). More
broadly, is becoming evident that oral dysbiosis is associated with
head and neck cancer development. Head and neck tumours
originate from several anatomical sites, each associated with
its own microbiota. Therefore, is possible that the crosstalk
between microbial populations, combined with known risk
factors, could drive head and neck carcinogenesis (Hayes et al.,
2018). Oral dysbiosis has been also involved in the pathogenesis
of systemic diseases. Indeed, recent studies indicate that oral
microbiota seems to be involved in the tumours of distant
organs, in particular “non-head and neck tumours” (Table 1;
Klimesova et al., 2018).
The aim of this article is to review the recent studies based
on genome sequencing to present evidences of a relationship
between oral microbiota and tumours of distant organs.
PANCREATIC CANCER
Pancreatic cancer (PC) is a malignant tumour with a 5-year
survival rate of 2–9% and a median survival time of 6 months
(Mcguigan et al., 2018). Although localised PCs have better
survival rate, these patients show absence or non-specific clinical
manifestations. The diagnostic delay leads to a fatal outcome,
with 80% of PCs that are unresectable at the time of presentation
(Vincent et al., 2011). Despite the study of thousands of blood
biomarkers for early detection of PC, none of them have
been validated for clinical use, suggesting a continuous change
of proteins expression over the course of disease evolution
(Yachida et al., 2010).
Several reports have demonstrated an association between
pathogenic microorganisms and PC, suggesting a role as
diagnostic biomarkers. Furthermore, is possible that bacterial
dysbiosis could contribute to the formation and progression of
PC (Wang and Li, 2015). In addition to the well-known risk
factors for PC, several studies have reported a positive association
between PC and oral health status. In particular, the relationship
between periodontal disease and tooth loss and an increased risk
of PC was found, suggesting that toxins exposure and increase
of systemic inflammation could promote tumour development
(Hujoel et al., 2003; Stolzenberg-Solomon et al., 2003; Michaud
et al., 2007). These findings led to the first studies on oral
microbiota describing the possible link between oral dysbiosis
and non-oropharyngeal cancers (Tables 1, 2).
In 2012was conducted the firstmicrobiota profiling of salivary
samples of patients affected by PC (Farrell et al., 2012). A
marked reduction of N. elongata and S. mitis and a significant
increase of G. adiacens, suggesting a link between variations
in oral microbiota and PC. In another study, saliva from 108
subjects was evaluated to determine microbiota profiles (Torres
et al., 2015). Although the overall microbiota diversity of the
groups was similar, a significative higher ratio of Leptotrichia
to Porphyromonas (LP ratio) was found in PC patients. Despite
the small sample size, salivary LP ratio was suggested as
a simple biomarker for PC. Moreover, this study confirmed
previous results showing that patients with high levels of plasma
antibodies to P. gingivalis were at higher risk of PC (Ahn
et al., 2012b; Michaud et al., 2013). Oral microbiota of patients
with intraductal papillary mucinous neoplasms (IPMN) and
pancreatic ductal adenocarcinoma (PDAC) was recently studied
(Olson et al., 2017). The results found similar overall microbiota
profile in saliva of PDAC and IPMN patients, but the mean
relative proportion of taxa among IPMN patients was between
that for PDAC patients and the controls. Recently, Fan et al.
conducted the first prospective case-control study with the aim
to evaluate microbiota profile in mouthwash samples taken from
PC patients and healthy controls (Fan et al., 2018). Although
no significant differences in overall microbiota composition
were found, P. gingivalis and A. actinomycetemcomitans were
associated with a higher risk of PC, while Fusobacteria and
Leptotrichia were associated with decreased tumour risk.
UPPER GASTROINTESTINAL TRACT
CANCER
Upper gastrointestinal cancers are characterised by non-specific
clinical manifestations, absence of effective treatments, and
changing epidemiological trends. Oesophageal cancer is the sixth
most common cause of cancer death, with a 5-year survival rate
of 15–25%. Histologically, the two main types are oesophageal
squamous cell carcinoma (SCC) and adenocarcinoma (AC)
(Domper Arnal et al., 2015). Microbiota seems to play a role in
oesophageal cancer aetiology, probably through the regulation
of the barrier function, the modulation of inflammation, or
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TABLE 1 | Published studies on the relationship between oral microbiota and tumours of distant organs, showing principal results.
References Cancer n◦ patients Sequencing technique
(instrument)
[16S rDNA hypervariable
regions]
Sample Validated
results
Main findings
Chen et al., 2015 EC 87 SCC,
63 dysplasia,
85 controls
Pyrosequencing (Roche 454
FLX Titanium) [V3–V4]
Saliva No Overall decreased microbial diversity in cancer patients. Oral microbiota of cancer and healthy subjects
clustered in opposite directions, while dysplasia patients were located between the 2 groups.
Peters et al., 2017 EC 81 AC,
25 SCC,
210 controls
Synthesis (Illumina MiSeq)
[V4]
Oral rinse No Overall microbial diversity of AC and SCC patients did not differ significantly from matched controls.
T. forsythia and P. gingivalis were more abundant in AC and SCC cases, respectively.
Snider et al., 2018 EC 32 Barrett
esophagus,
17 control
Synthesis (Illumina HiSeq
2500) [V4]
Oral swab Yes A 3-taxon model (Lautropia, Streptococcus, and an unspecified genus of the order Bacteroidales)
discriminated between Barrett and controls (AUC = 0.94). Cancer patients with Barrett showed
increased levels of Enterobacteriaceae.
Hu et al., 2015 GC 34 GC,
17 controls
Synthesis (Illumina MiSeq)
[V2–V4]
Tongue coat No Overall diversity of tongue coating microbiota was reduced in “thick tongue” phenotype. Thick tongue
coating was associated with gastric cancer.
Sun et al., 2018 GC 37 GC,
13 controls
Synthesis (Illumina MiSeq)
[V4]
Saliva,
plaque
No Overall increased microbial diversity in cancer patients. A scoring system based on 11 different genera
was used to screen gastric cancer (sensitivity = 97%, false positivity rate = 7.7%).
Wu et al., 2018 GC 57 GC,
80 controls
Pyrosequencing (Roche 454
GS-FLX) [V4]
Tongue coat No 6 bacterial clusters were identified to distinguish cancer patients from controls. Cancer patients showed
less abundant bacterial clusters 1–2 and more abundant bacterial cluster 3–6 (cluster 6 had AUC =
0.76).
Farrell et al., 2012 PC 10PC,
10 controls
Microarray assay (HOMIM
array)
Saliva Yes 2-biomarker model (N. elongata and S. mitis) distinguished cancer patients from healthy controls (AUC =
0.90). 2-biomarker model (G. adiacens and S. mitis) distinguished cancer patients from chronic
pancreatitis (AUC = 0.68).
Torres et al., 2015 PC 8PC,
78 other
disease,
22 controls
Synthesis (Illumina MiSeq)
[V4]
Saliva No Overall microbiota diversity of the three groups was very similar. Significative higher ratio of Leptotrichia
to Porphyromonas was found in cancer patients.
Olson et al., 2017 PC 40 PDAC,
39 IPMN,
58 controls
Synthesis (Illumina MiSeq)
[V4–V5]
Saliva No Overall microbiota in PDAC and IPMN patients was very similar. PDAC cases showed higher proportion
of Firmicutes and related taxa.
Fan et al., 2018 PC 361PC,
371 controls
Pyrosequencing (Roche 454
FLX Titanium) [V3–V4]
Oral rinse No P. gingivalis and A. actinomycetemcomitans were associated with a higher risk of cancer. Fusobacteria
and Leptotrichia were associated with decreased risk of cancer.
Han et al., 2014 CRC 47 CRC,
45 controls
Synthesis (Illumina MiSeq)
[V2–V4]
Tongue coat No Thick tongue coating was associated with cancer patients and microbiota imbalance on the tongue was
related to the changes in tongue coating.
Kato et al., 2016 CRC 68 CRC,
122 controls
Synthesis (Illumina MiSeq)
[V3–V4]
Oral rinse No Colorectal cancer was associated with increased presence of Lactobacillus and Rothia. The differences
of overall microbiota between smokers and non-smokers were higher in cancer patients.
Russo et al., 2017 CRC 10 CRC,
10 controls
Synthesis (Illumina MiSeq)
[V3–V4]
Saliva No There were no significant differences in salivary microbiota between cancer patients and controls.
Flemer et al., 2018 CRC 45 CRC,
21 polyps,
25 controls
Synthesis (Illumina MiSeq)
[V3–V4]
Oral swab No Overall microbiota differs between cancer patients and controls. A specific oral and faecal microbiota test
discriminated healthy controls from patients with cancer and polyps (AUC = 0.94 and 0.98, respectively).
Yang et al., 2018 CRC 231 CRC,
461 control
Synthesis (Illumina HiSeq)
[V4]
Oral rinse No T. denticola and P. intermedia were associated with increased cancer risk. Furthermore, 11 common and
16 rare taxa were also associated with cancer risk.
Wang et al., 2014 ALL 13 ALL,
12 controls
Pyrosequencing (Roche 454
GS-FLX) [V1–V3]
Plaque No ALL patients had reduced overall microbial diversity. Moreover, “leukemia-associated” taxa were
detected.
(Continued)
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the direct metabolism of carcinogens (Peters et al., 2017).
Furthermore, periodontal disease seems to be associated with
increased cancer risk, suggesting a role of oral microbiota
(Michaud et al., 2007).
Salivary microbiota of oesophageal SCC, oesophageal
dysplasia, and healthy subjects were compared, showing
reduction of several genera in cancer patients (Chen et al.,
2015). Overall oral microbiota of oesophageal SCC and controls
clustered in opposite directions, while dysplasia patients were
located between the 2 groups. Oral microbiota profiling was
prospectively studied in oesophageal SCC and AC, using pre-
diagnostic oral wash samples from cancer and healthy cohorts,
but lack of significant diversity between cancer patients and
matched controls was found (Peters et al., 2017). Nevertheless,
two periodontal pathogens, T. forsythia and P. gingivalis, were
more abundant in oesophageal AC and SCC cases, respectively. A
recent work evaluated the feasibility of early detection of Barrett’s
oesophagus through the assessment of oral microbiota (Snider
et al., 2018). A 3-taxon model including Lautropia, Streptococcus,
and a genus of the order Bacteroidales distinguished Barrett’s
oesophagus from controls with high sensitivity (96.9%) and
specificity (88.2%) (Tables 1, 2).
Gastric cancer (GC) is the third most common cause of cancer
death, with a 5-year survival rate of 30%. Interestingly, 5-year
survival rate in Japan is 70% for early stages of GC, suggesting the
feasibility of mass screening programs (Karimi et al., 2014). The
well-established role of H. pylori in GC development has given
rise to the hypothesis that oral microbial dysbiosis could promote
GC development (Ahn et al., 2012a). Several epidemiological
studies corroborated such hypothesis showing the association
between periodontal disease and tooth loss and an increased risk
of GC (Stolzenberg-Solomon et al., 2003; Michaud et al., 2017).
These findings led to the search for oral microbial biomarkers
that allow an early and non-invasive diagnosis of GC (Table 1).
The relationship between tongue coating appearance and
tongue microbiota profiling was investigated in GC patients
and healthy controls (Hu et al., 2015). Tongue coating was
significantly ticker in GC patients and was associated with
reduced overall microbial diversity. Another study explored the
alterations of tongue coating microbiota in patients with newly
diagnosed GC and healthy controls, demonstrating a significative
lower ratio of Bacteroidetes to Firmicutes in GC, especially in
non-cardia GC patients (Wu et al., 2018). A recent case-control
study was conducted with the aim to investigate the microbial
community of both salivary and subgingival plaque in GC
patients (Sun et al., 2018). Although saliva and plaque showed
two different microbiotas, the overall microbial diversity was
significantly increased in GC patients, and a screening system
based on 11 different genera demonstrated high sensitivity
(97%) (Table 2).
LOWER GASTROINTESTINAL TRACT
CANCER
Colorectal cancer (CRC) is one of the most diagnosed
malignancy and the second most common cause of cancer
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TABLE 2 | Comparison of microbial composition at the genus level in cancer patients.
Cancer Increased microbes (genus) Reduced microbes (genus) References
EC Streptococcus, Veillonella Neisseria, Rothia, Haemophilus Chen et al., 2015; Peters et al., 2017; Snider et al., 2018
GC Streptococcus, Veillonella Neisseria, Rothia, Leptotrichia Sun et al., 2018; Wu et al., 2018
PC Streptococcus Neisseria, Haemophilus, Leptotrichia Torres et al., 2015; Olson et al., 2017; Fan et al., 2018
CRC Rothia, Actinomyces, Lactobacillus Streptococcus, Neisseria, Haemophilus Han et al., 2014; Kato et al., 2016; Flemer et al., 2018; Yang et al., 2018
ALL/AML Veillonella, Streptococcus Leptotrichia Wang et al., 2014; Galloway-Peña et al., 2017
LC Veillonella Neisseria Yan et al., 2015
HC Leptotrichia Streptococcus, Haemophilus Lu et al., 2016
Only main microbial species were reported (for further details, see Supplementary Table 1). Interestingly, expression levels of genus Streptococcus change significantly depending on
tumour type. EC, oesophageal cancer; GC, gastric cancer; PC, Pancreatic cancer; CRC, colorectal cancer; ALL/AML, Acute lymphoblastic leukaemia/acute myeloid leukaemia; LC,
lung cancer; HC, hepatic cancer.
death (Marley and Nan, 2016). A possible association between
gut dysbiosis and CRC have been suggested. Indeed, both
the whole colon microbiota and specific pathogens seems to
contribute to the formation and progression of CRC (Klimesova
et al., 2018). Findings of colonization of CRC tissues by typical
oral bacteria raised the hypothesis of a possible involvement of
oral microbiota in CRC development. The possible link between
oral microbiota and CRC has been suggested by the fact that
each day 1011 oral bacteria reach colorectal mucosa, influencing
local microbiota (Klimesova et al., 2018). Furthermore, several
epidemiological investigations suggested an association between
periodontal disease and CRC (Hu et al., 2018). Although the
interactions between CRC and the oral-gut microbiota axis
are poorly understood, several studies have been conducted to
investigate the role of oral bacteria as diagnostic biomarkers for
CRC (Table 1).
Han et al. evaluated the relationship between tongue coating
appearance and microbiota profiling in patients with CRC (Han
et al., 2014). The results were similar to those obtained by
the same research group in GC (Hu et al., 2015), showing
a significant association between “thick tongue” phenotype
and overall microbiota imbalance, especially in CRC patients.
Another study investigated the association of smoking and CRC
history with oral microbiota profile (Kato et al., 2016). The
results failed to support earlier observations about the association
between F. nucleatum and CRC, although increased presence of
Lactobacillus and Rothia genera was found in cancer patients.
Furthermore, smoking status was associated with a decrease in
Betaproteobacteria class and Veilonellaceae family, especially in
CRC patients. Microbial communities in a small group of CRC
patients were investigated by comparingmicrobiota profiles from
saliva, faeces and tissue samples (Russo et al., 2017). Although an
altered microbial composition in faecal samples of CRC patients
was noted, the differences in oral microbiota between cancer
patients and healthy controls were inconsistent. A recent study
compared microbiotas from faecal samples and colonic mucosa
with oral microbiota in a larger cohort of patients (45 with
CRC, 21 with colorectal polyps, and 25 healthy controls) (Flemer
et al., 2018). Overall microbiota differs significantly between CRC
patients and controls, suggesting that the colonic establishment
of a putatively pathogenic oral-like community is more frequent
in patients with CRC or polyps. Moreover, a specific oral
and faecal microbiota test discriminated healthy controls from
CRC patients with high sensitivity (76%) and specificity (94%).
Recently, a large prospective case-control study investigated the
association of specific periodontal pathogens and the overall oral
microbiota with subsequent risk of CRC (Yang et al., 2018). The
results showed a significant relationship between CRC risk and
higher levels of T. denticola and P. intermedia. Furthermore, 11
common and 16 rare taxa seemed to be associated with cancer
risk, especially among African-American and females.
OTHER TUMOURS
The promising results obtained by oral microbiota studies in
gastrointestinal cancers led several research groups to investigate
the diagnostic/prognostic applications of oral microbiota in
other tumours. Although promising, these results are highly
preliminary and far less clear than those reported in the
aforementioned studies (Tables 1, 2).
Among the blood cancers, leukaemia is frequently associated
with oral manifestations, like periodontitis and candidiasis.
Therefore, imbalance of commensal oral microflora could be
related to higher risk of both oral and systemic infections
(Pa˘unica˘ et al., 2009). Oral microbiota profiling was evaluated
in paediatric patients affected by acute lymphoblastic leukaemia
(Wang et al., 2014). In particular, a genome analysis was
conducted on supragingival plaque microbiota in 13 ALL
patients, showing a reduced overall microbial diversity and
detecting a specific pool of leukaemia-associated taxa. A
longitudinal study was conducted on patients with acute myeloid
leukaemia, with the aim to evaluate the variability of oral and
gut microbiota during induction chemotherapy (Galloway-Peña
et al., 2017). The results highlighted a high intra-patient temporal
variability of oral microbiota and a correlation with higher risk of
infection after induction chemotherapy.
Among solid malignancies, oral microbiota profile was
investigated in lung cancer (LC) patients (Yan et al., 2015).
Salivary samples from patients with SCC and AC showed overall
microbiota difference between cancer patients and healthy
controls. Furthermore, scoring system based on 2 genera,
Veillonella and Capnocytophaga, distinguished healthy controls
from SCC and AC. Another high-throughput sequencing-based
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 June 2019 | Volume 9 | Article 232
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study investigated tongue coatingmicrobiota in cirrhotic patients
with hepatic cancer (HC), finding an increased overall microbial
diversity (Lu et al., 2016). Furthermore, 2 genera, Oribacterium
and Fusobacterium, discriminated between HC patients and
healthy controls. Finally, Wang et al. compared oral and urinary
microbiota from 57 patients with breast cancer (BC) and 21
healthy subjects, but lack of significant relationship between oral
microbiota and the presence of BC was found (Wang et al., 2017).
CONCLUSIONS
Overall, the results presented here showed a significant shift
in oral microbiota composition between cancer patients and
healthy controls. For example, Firmicutes and Actinobacteria
were the most predominant phyla in cancer patients,
while Proteobacteria, Fusobacteria, and Bacteroides were
significantly more abundant in healthy controls (Table 2).
Recently, the concept of resilience has been applied to the
oral microbiota, defined as the capacity of this microbial
ecosystem to deal with perturbation without shifting to
potentially harmful states (Rosier et al., 2018). Strong and
persistent perturbations to the oral environments can disrupt
resilience, leading to a “regime shift” toward oral dysbiosis and,
ultimately, to an increased risk of oral and systemic disease
(Marsh, 2003).
Unfortunately, these results are heterogeneous among the
studies, especially regarding specific cancer types, and do not
allow drawing general conclusions. In particular, oral microbiota
alterations seem to be more pronounced in patients with
gastrointestinal tumours, paving the way for developing specific
tests to allow early detection of cancer (Farrell et al., 2012; Torres
et al., 2015; Flemer et al., 2018; Snider et al., 2018). The overlap
between the microbiotas of oral cavity and gastrointestinal tract,
probably due to colonization of gut mucosa by oral bacteria,
could partially explain these results (Flynn et al., 2016).
There are several factors that currently limit the generalization
of these results. First of all, the small sample size, mainly
due to the high sequencing cost, limits the statistical power
of the studies. Furthermore, lack of adequate information
about patients (e.g., oral health status, active smoking, and
antibiotic use) is a source of confounding factors (Snider
et al., 2018). Most studies are conducted cross-sectionally,
a design that is unable to infer causality between oral
dysbiosis and tumour development. This aspect is particularly
important, because the alternative hypothesis is the so-
called “reverse causality,” namely that modifications in the
normal oral microbiota are the result of tumour progression,
secondary to systemic processes (Fan et al., 2018). Indeed,
although different pathogenic mechanisms have been proposed,
direct evidence is not yet available and the reverse causality
cannot be excluded. In particular, oral microbiota could be
involved in cancer development, but specific tissue tropism
for microbial translocation and molecular mechanisms of
microbiota-driven carcinogenesis at distal sites are yet to be
proven (Chen et al., 2017).
Regarding methodological aspects, different types of oral
samples were evaluated making the comparison of these
microbial communities difficult. Bacteria colonize all sites
within the oral cavity, forming different habitats, each with
different non-overlapping microbial populations (Jia et al., 2018).
Therefore, it is important to develop a method that can access
all oral sites and the microbial diversity inherent to them (Lim
et al., 2017). Saliva is the most commonly studied sample, due to
several features that make it ideal for research purposes. Thanks
to its role in “ecological stability” of oral cavity, saliva allows to
early detect an overall dysbiotic trend of oral microbiota (Rosier
et al., 2018; Belibasakis et al., 2019). Although different collection
methods can alter salivary microbiota (e.g., muscle movements
from spitting action may provide larger microbial coverage
compared with passive drooling), this seems to not significantly
affect the overall microbial composition (Lim et al., 2017). The
studies reported here used different sequencing techniques and
analysed different 16S rDNA hypervariable regions, with an
increased risk for ambiguous data for some rare bacterial species
(Table 1; Verma et al., 2018). Furthermore, sequencing depth
of these studies could not be sensitive enough to adequately
describe differences in oral microbiota in patients with and
without tumour (Teng et al., 2018).
Nevertheless, the evidences linking oral microbiota
with different tumours are promising. Furthermore,
metatranscriptomic and metabolomic analyses are making a
significant contribution to the understanding of the relationship
between oral microbiota metabolism and human health (García-
Castillo et al., 2016). The demonstration of a direct causality
between oral dysbiosis and risk of tumour development could
lead to new prevention strategies. This could also lead to a
broader definition of oral health, including also the presence of a
stable microbial homeostasis. Furthermore, causal link between
oral microbiota and cancer could contribute to the search for
new biomarkers (e.g., markers of resilience) and new therapeutic
anticancer strategies, such as the use of pre- and pro-biotics
(Rosier et al., 2018).
Although only at the beginning, oral microbiota analysis could
be the next step in the evolution of cancer therapy and will help
clinicians to develop tailored prevention and treatment strategies.
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